Alnylam Q3 2026 earnings beat but shares tumble as demand growth stalls and guidance trimmed

Alnylam Pharmaceuticals reported third‑quarter 2026 revenue growth of roughly 50% year‑over‑year, driven by its TTR franchise and AMVUTTRA sales. Management said the expanded sales force has not yet translated into new patient starts and lowered full‑year TTR product sales guidance to the low end of $4.2‑$4.5 billion. The company also expanded the TRITON‑CM nucresiran trial enrollment to about 2,250 patients. Despite the earnings beat, the stock fell about 25% on the day.

The lower‑end guidance signals slower top‑line growth than previously expected, which may pressure analysts’ revenue forecasts (BMO cut its price target to $290, UBS to $329). The share‑price decline reflects investor concern over demand‑growth headwinds and potential 340B reimbursement changes.

  • 1Total revenue for Q3 2026 was $1.46 billion, a 17% year‑over‑year increase.
  • 2Global net product revenue grew 52% year‑over‑year to $1.29 billion.
  • 3TTR franchise revenue was $1.15 billion, up 59% year‑over‑year.
  • 4AMVUTTRA sales were $1.13 billion, up 65% year‑over‑year and 10% sequentially.
  • 5Full‑year TTR product sales guidance was set at $4.2 billion to $4.5 billion, with management expecting results at the low end.
  • 6TRITON‑CM nucresiran trial enrollment target was expanded to 2,250 patients.
  • Total revenue is reported as $1.46 billion in material 10 and $1.3 billion in material 5, a conflict on the same metric.

Sources